Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Penta Valent TbkISX:PEVE 15 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates ISX:PEVE with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 477 Healthcare Providers & Services companies, PT Penta Valent Tbk ranks worse than 209643.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Penta Valent Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:PEVE's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.18 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Penta Valent Tbk Debt-to-EBITDA Related Terms
PT Penta Valent Tbk Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PT Penta Valent Tbk's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, PT Penta Valent Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Penta Valent Tbk Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Penta Valent Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Penta Valent Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (. 20) EBITDA data.
PT Penta Valent Tbk (ISX:PEVE) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Penta Valent Tbk. According to the industry distribution chart, PT Penta Valent Tbk ranks #999999 out of 477 companies in the Healthcare Providers & Services industry.
Is PT Penta Valent Tbk's Debt-to-EBITDA too high?
PT Penta Valent Tbk's current Debt-to-EBITDA is 0.00. Based on the distribution chart, PT Penta Valent Tbk ranks #999999 out of 477 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PT Penta Valent Tbk has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does PT Penta Valent Tbk's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PT Penta Valent Tbk ranks #999999 out of 477 companies for Debt-to-EBITDA. This places PT Penta Valent Tbk in the lower half of its industry. The industry median Debt-to-EBITDA is 2.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.18, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Penta Valent Tbk. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Penta Valent Tbk's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Penta Valent Tbk stock overvalued right now?
PT Penta Valent Tbk (ISX:PEVE) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. PT Penta Valent Tbk's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Penta Valent Tbk (ISX:PEVE), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Penta Valent Tbk is engaged in the distribution of pharmaceutical products, medical equipment, and consumer products. The company divides its business into two segments that contribute to the company's operating revenues, namely Pharmaceutical Products and Consumer Products. It generates the majority of the revenue from the Pharmaceutical Products segment. Pharmaceutical Segment a special segment for distributing pharmaceutical products or medicines and medical devices. Geographically, the company operates in Java and Outside Java, of which derives maximum revenue from Java.
15GF Score
Get the complete analysis for ISX:PEVE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PEVE has been successfully added to your 
